#USA #Fremont #Alamar Biosciences #NULISAqpcr #Alzheimer's Research

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay

Alamar Biosciences, a pioneering company in precision proteomics, has made a significant advancement in Alzheimer’s research with the launch of their NULISAqpcr™ BD-pTau217 Assay. This novel assay offers precise detection of the phosphorylated tau 217 (pTau217) biomarker, which has been crucial in understanding Alzheimer’s disease and related tauopathies. With its introduction, the NULISAqpcr™ BD-pTau217 is set to redefine the landscape of non-invasive testing for this neurodegenerative disorder.

Transformative Technology for Alzheimer’s Research

The NULISAqpcr™ BD-pTau217 Assay is unique in being the only single-plex assay available on the market that measures brain-derived pTau217 levels from peripheral blood samples. This capability eliminates the need for invasive procedures such as lumbar punctures or PET imaging, making it far more accessible for both large population studies and longitudinal clinical trials. Dr. Yuling Luo, the founder and CEO of Alamar Biosciences, expressed enthusiasm about the assay, stating, "The NULISAqpcr BD-pTau217 Assay redefines the possibilities for quantifying CNS biomarkers. By removing the noise from peripheral tau sources, researchers can now detect meaningful changes in the brain earlier and with greater precision."

Dr. Jonathan Schott, a professor of neurology at University College London, echoed this sentiment, highlighting the assay's effectiveness: "The performance of Alamar's brain-specific pTau217 plasma tests is outstanding. Early results indicate that our single-plex format performs at least as well as established pTau217 plasma tests while exhibiting a higher fold-change and fewer ambiguous results. In research, measurements of brain-specific pTau levels using the multiplex assay show promise for identifying asymptomatic individuals with high Alzheimer pathology who qualify for clinical trials with disease-modifying therapies."

Features and Benefits of the NULISAqpcr™ BD-pTau217 Assay

This assay utilizes Alamar's proprietary NULISA™ platform, providing unprecedented sensitivity and specificity for non-invasive sample types such as plasma, serum, and dried blood spots. The streamlined workflow allows the processing of over 220 samples per day using the ARGO™ HT System, making it perfect for high-throughput analyses in both disease cohorts and population-based studies.

The development of the NULISAqpcr™ BD-pTau217 Assay heralds a new era in Alzheimer’s research by providing researchers with a powerful tool to study disease mechanisms and treatment responses without the need for complex and invasive methodologies. This breakthrough can lead to earlier intervention strategies and improved outcomes for those at risk of Alzheimer’s disease.

Future Directions

As part of its dedication to advancing neuroscience, Alamar Biosciences continues to collaborate with the broader scientific community to gain deeper insights into biomarkers that can accelerate progress in Alzheimer’s disease and beyond. The NULISA BD-pTau217 Assays are intended strictly for research purposes and are not applicable for diagnostic procedures. For more information, visit alamarbio.com.

In summary, the NULISAqpcr™ BD-pTau217 Assay symbolizes a pivotal step in transforming Alzheimer’s research, paving the way for groundbreaking discoveries and enhancing our understanding of neurodegenerative diseases.